Direct oral anticoagulants to treat left ventricular thrombus—A systematic review and meta‐analysis: ELECTRAM investigators. (1st April 2021)

• Record Type: Journal Article
• Authors: Shah, Siddharth; Shah, Kuldeep; Turagam, Mohit K.; Sharma, Abhinav; Natale, Andrea; Lakkireddy, Dhanunjaya; Garg, Jalaj
• Is Part Of: Journal of cardiovascular electrophysiology. Volume 32:Number 6(2021)
• Page Start: 1764
• Page End: 1771
• Publication Date: 2021-04-01
• Subjects: direct oral anticoagulants -- left ventricular thrombus -- vitamin K antagonists -- warfarin; Blood vessels -- Physiology -- Periodicals; Electrophysiology -- Periodicals; Heart -- Physiology -- Periodicals; 612.1
• DOI: 10.1111/jce.15016
• Languages: English
• ISSNs: 1045-3873

Abstract

Abstract: Introduction: Though current guidelines currently recommend using warfarin, there is also a growing interest in the utilization of direct oral anticoagulants (DOACs) to treat left ventricular (LV) thrombus. Methods: We performed a systematic search using PubMed, SCOPUS, EMBASE, Google Scholar, and ClinicalTrials.gov from inception to September 30, 2020, for studies that had reported outcomes in patients with left ventricular thrombus treated with DOACs (PROSPERO registration number CRD42020219761). Results: Twelve studies ( n = 867 patients) were included in the analysis. The pooled incidence of the systemic embolic events (SEE) with DOACs was 2.7%, whereas the thrombus resolution rate was 86.6%. The pooled incidence of overall bleeding (composite of major and minor bleeding) and major bleeding with DOACs were 5.6% and 1.1%, respectively. No significant difference was observed in terms of SEE (OR 0.81, 95% confidence interval [CI] 0.44–1.52, p = .54), major bleeding (OR 0.29, 95% CI 0.07–1.26, p = .24), and failure of LV thrombus resolution (OR 0.86, 95% CI 0.28–2.58, p = .68); whereas overall bleeding was significantly low in patients with LV thrombus treated with DOACs compared to vitamin K antagonists (VKAs) (OR 0.33, 95% CI 0.14–0.81, p = .02). Conclusion: Our study demonstrates no significant difference in SEE, major bleeding, or failure of LV thrombus resolution between the two groups, thus demonstrating that DOACs are an efficacious and safe alternative for the treatment of LV thrombus compared to VKAs. However, further well‐designed prospective trials are needed to answer important clinical questions—optimal dosing/duration of DOACs and its safety in the background of antiplatelet therapy.